SCHEDULE: Great Point Partners Discloses 5.63% Stake in VOR Biopharma

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a 5.63% beneficial ownership stake in VOR Biopharma Inc. common stock.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 1,234,486 shares of VOR Biopharma Inc. common stock.
• This ownership represents 5.63% of VOR Biopharma Inc.'s outstanding common stock.
• The shares are held through Biomedical Value Fund, L.P. (851,794 shares) and Biomedical Offshore Value Fund, Ltd. (382,692 shares), for which Great Point Partners, LLC serves as the investment manager.
• Dr. Jeffrey R. Jay, M.D., as Senior Managing Member, and Ms. Lillian Nordahl, as Managing Director of Great Point Partners, LLC, possess shared voting and investment power over these shares.
• The percentage of class is calculated based on 21,910,630 shares outstanding, as reported by VOR Biopharma Inc. in its Prospectus 424B3 filed on December 1, 2025.
• The reporting persons disclaim beneficial ownership of the shares except to the extent of their respective pecuniary interests.
• The filing indicates a passive investment intent, certifying that the securities were not acquired or held for the purpose of changing or influencing the control of VOR Biopharma Inc.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of ownership and does not contain qualitative information about company performance or future prospects.

Future Outlook

NA

Management Comments

• The Reporting Persons have entered into a Joint Filing Agreement, dated December 17, 2025, pursuant to which the Reporting Persons have agreed to file this statement jointly.
• Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interests.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.

Key Dates

Keywords

VOR Biopharma, Great Point Partners, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biopharma, Investment Management